BioCentury
ARTICLE | Finance

1 in 100

Atlas Venture sharpens target profile for biotech, pharma products to license

October 8, 2012 7:00 AM UTC

Now approaching its second birthday, Atlas Venture Development Corp has formed single-asset companies from only two of the 200 in-licensing candidates that have crossed its radar.

But in the process, the venture firm's asset-centric project arm has homed in on a product profile it thinks will work for both it and the out-licensor. AVDC thus is looking to complete up to two more deals by the end of 1H13...